6-Sulfanilamidoindazole arthritis in rats: influence of the new anti-inflammatory agent CGP 28237 and of the immunomodulating compound HWA 486 on degree of arthritis and on acute phase reaction.
D000210:Acute-Phase Reaction / Q000188:drug therapy*; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001168:Arthritis / Q000188:drug therapy*; D001169:Arthritis, Experimental / Q000188:drug therapy* / Q000503:physiopathology; D007189:Indans / Q000627:therapeutic use*; D007192:Indenes / Q000627:therapeutic use*; D007249:Inflammation / Q000188:drug therapy*; D007555:Isoxazoles / Q000627:therapeutic use*; D000077339:Leflunomide; D010080:Oxazoles / Q000627:therapeutic use*; D051381:Rats; D013424:Sulfanilamides
D000894:Anti-Inflammatory Agents, Non-Steroidal; D007189:Indans; D007192:Indenes; D007555:Isoxazoles; D010080:Oxazoles; D013424:Sulfanilamides; C009347:6-sulfanilamidoindazole; C054253:5-methylsulfonylamino-6-phenoxy-1-indanone; D000077339:Leflunomide